Corient Private Wealth LLC Has $22.28 Million Stake in West Pharmaceutical Services, Inc. (NYSE:WST)

Corient Private Wealth LLC decreased its position in West Pharmaceutical Services, Inc. (NYSE:WST) by 0.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 63,259 shares of the medical instruments supplier’s stock after selling 210 shares during the quarter. Corient Private Wealth LLC’s holdings in West Pharmaceutical Services were worth $22,275,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in WST. Norges Bank acquired a new stake in West Pharmaceutical Services during the fourth quarter worth approximately $300,250,000. Artisan Partners Limited Partnership increased its position in shares of West Pharmaceutical Services by 57.2% in the third quarter. Artisan Partners Limited Partnership now owns 1,591,271 shares of the medical instruments supplier’s stock worth $597,061,000 after purchasing an additional 578,796 shares during the period. Massachusetts Financial Services Co. MA acquired a new position in West Pharmaceutical Services in the third quarter valued at about $215,011,000. Findlay Park Partners LLP lifted its position in West Pharmaceutical Services by 65.2% during the fourth quarter. Findlay Park Partners LLP now owns 457,306 shares of the medical instruments supplier’s stock worth $161,027,000 after purchasing an additional 180,415 shares during the period. Finally, Rhenman & Partners Asset Management AB lifted its position in West Pharmaceutical Services by 1,900.0% during the third quarter. Rhenman & Partners Asset Management AB now owns 180,000 shares of the medical instruments supplier’s stock worth $67,538,000 after purchasing an additional 171,000 shares during the period. Institutional investors and hedge funds own 93.90% of the company’s stock.

West Pharmaceutical Services Stock Down 1.7 %

Shares of NYSE:WST opened at $328.59 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.95 and a current ratio of 2.61. West Pharmaceutical Services, Inc. has a 52-week low of $310.42 and a 52-week high of $415.73. The company has a market capitalization of $23.93 billion, a PE ratio of 43.35, a price-to-earnings-growth ratio of 5.90 and a beta of 1.05. The company has a fifty day moving average of $374.80 and a 200-day moving average of $363.84.

West Pharmaceutical Services (NYSE:WST) last issued its earnings results on Thursday, April 25th. The medical instruments supplier reported $1.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.29 by $0.27. West Pharmaceutical Services had a return on equity of 20.57% and a net margin of 19.42%. The business had revenue of $695.40 million during the quarter, compared to analysts’ expectations of $670.62 million. During the same quarter in the prior year, the firm earned $1.98 EPS. The business’s revenue for the quarter was down 3.0% compared to the same quarter last year. On average, equities analysts predict that West Pharmaceutical Services, Inc. will post 7.76 EPS for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, August 7th. Shareholders of record on Wednesday, July 31st will be issued a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a yield of 0.24%. The ex-dividend date is Wednesday, July 31st. West Pharmaceutical Services’s payout ratio is 10.55%.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Jefferies Financial Group raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and raised their target price for the company from $323.00 to $536.00 in a report on Wednesday, February 7th. UBS Group decreased their price objective on shares of West Pharmaceutical Services from $400.00 to $375.00 and set a “neutral” rating on the stock in a research note on Friday, February 16th. StockNews.com cut West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research note on Friday, February 16th. Finally, KeyCorp lifted their price target on West Pharmaceutical Services from $440.00 to $470.00 and gave the company an “overweight” rating in a research note on Tuesday, February 13th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $435.20.

Insider Buying and Selling at West Pharmaceutical Services

In other news, CEO Eric Mark Green sold 64,132 shares of West Pharmaceutical Services stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $359.85, for a total transaction of $23,077,900.20. Following the transaction, the chief executive officer now owns 152,908 shares in the company, valued at $55,023,943.80. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, VP Charles Witherspoon sold 2,019 shares of the business’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $358.62, for a total value of $724,053.78. Following the transaction, the vice president now owns 1,979 shares in the company, valued at approximately $709,708.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Eric Mark Green sold 64,132 shares of the stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $359.85, for a total transaction of $23,077,900.20. Following the sale, the chief executive officer now owns 152,908 shares of the company’s stock, valued at $55,023,943.80. The disclosure for this sale can be found here. In the last ninety days, insiders sold 132,966 shares of company stock worth $48,293,292. 0.53% of the stock is currently owned by company insiders.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.